Non-Alcoholic Steatohepatitis (NASH) Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Non-Alcoholic Steatohepatitis (NASH) Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for non-alcoholic steatohepatitis (NASH) has experienced rapid expansion in recent years, increasing from $6.06 billion in 2025 to $8.04 billion in 2026, reflecting a compound annual growth rate (CAGR) of 32.7%. This historical growth was driven by factors such as insufficient public awareness of NASH, a scarcity of effective therapeutic solutions, a dependence on lifestyle changes, a high incidence of metabolic conditions, and a disjointed market structure.
The non-alcoholic steatohepatitis (NASH) market is projected to undergo substantial expansion in the coming years, with its value anticipated to reach $24.32 billion by 2030, representing a compound annual growth rate (CAGR) of 31.9%. This forecasted growth is driven by factors such as progress in targeted therapies, rising healthcare spending, a growing shift toward non-invasive diagnostic methods, an expanding pipeline of pharmaceutical products, and enhanced collaborative efforts in research and development. Additionally, key trends shaping the market over the forecast period include the growing incidence of obesity and type 2 diabetes, the emergence of non-invasive diagnostic tools, intensified research into therapies for liver fibrosis, the rise of personalized and targeted drug treatments, and the broadening of hospital and retail pharmacy networks.
Download A Free Sample Report For Comprehensive Market Insights:
Non-Alcoholic Steatohepatitis (NASH) Market Expansion Supported By Key Demand Factors
The growing prevalence of obesity is fueling demand in the non-alcoholic steatohepatitis (NASH) market. Obesity is defined as an abnormal or excessive accumulation of fat that presents a health risk, along with a body weight exceeding what is considered healthy or normal for an individual of a given height. As the global obesity epidemic intensifies, non-alcoholic fatty liver disease has become more common, positioning NASH as a potential leading cause of severe liver conditions in the coming decades—this, in turn, is driving the need for NASH treatments and related pharmaceuticals. For example, in May 2025, data from the Government Digital Service, a UK-based government body, revealed that during 2023 to 2024, the prevalence of overweight (including obesity) among adults was higher in men (69.7%) compared to women (59.2%), whereas obesity rates were higher in women (26.9%) than in men (26.2%). Consequently, the increase in obesity cases is expected to propel growth in the non-alcoholic steatohepatitis (NASH) market.
Non-Alcoholic Steatohepatitis (NASH) Market Segment Landscape And Growth Potential
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Non-Alcoholic Steatohepatitis (NASH) Market Growth Trends Influencing Competitive Dynamics
Key players in the non-alcoholic steatohepatitis (NASH) market are concentrating on the development of thyroid hormone receptor-beta (THR-beta) agonists, which are designed to boost liver metabolism, decrease the buildup of fat in the liver, and enhance overall liver function. These THR-beta agonists work by specifically targeting and activating the thyroid hormone receptor-beta subtype, a crucial receptor that regulates metabolic processes, growth, and development. A notable example occurred in March 2024, when the U.S.-based Food and Drug Administration gave its approval to Rezdiffra (resmetirom), a THR-beta agonist, marking it as the first therapeutic option for adults suffering from noncirrhotic NASH accompanied by moderate to advanced liver scarring, or fibrosis. Through its selective activation of the THR-beta receptor, Rezdiffra effectively modulates lipid metabolism, resulting in a significant reduction in intrahepatic triglycerides and a decrease in total liver fat accumulation.
Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens
Access The Complete Non-Alcoholic Steatohepatitis (NASH) Market Report:
Non-Alcoholic Steatohepatitis (NASH) Market Regional Analysis And Leading Geography
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
